Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Doctors consulting

Helping to Reshape NASH Clinical Trials

ELF Test indicated as top-performing biomarker in NIMBLE study

Siemens Healthineers is proud to be recognized in Stage I of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study.

The results of the study were recently presented at The Liver Meeting 2021 and showed that the Enhanced Liver Fibrosis (ELF™) Test performed the best of the five blood biomarkers selected for the study.

View Abstract: Primary Results of the NIMBLE Stage 1-NASH CRN Study of Circulating Biomarkers for Nonalcoholic Steatohepatitis and its Activity and Fibrosis Stage

Find out More